黑色素瘤靶向治疗药物研究进展  

Research Progress of Melanoma Targeted Therapeutics

作　　者：刘可微 张坤[1,2] 刘侠 康淑霞[1,2] 郝玉琴 LIU Kewei;ZHANG Kun;LIU Xia;KANG Shuxia;HA O Yuqin(Inner Mongolia Medical University,Hohhot 010110,China;Department of Dermatology ＆ S TD,the Third Affiliated Hospital of Inner Mongolia Medical University,Baotou 014010,China)

机构地区：[1]内蒙古医科大学,呼和浩特010110 [2]内蒙古医科大学第三附属医院皮肤性病科,内蒙古包头014010

出　　处：《医学综述》2018年第20期4004-4009,共6页Medical Recapitulate

摘　　要：在过去的几年中,黑色素瘤发病机制及发展过程中涉及的致癌基因和信号通路得到了全面深入的研究,治疗方案也有了显著改善。目前,除已经在临床治疗中使用的靶向药物外,一些正在进行临床研究的待批准药物和正在进行基础研究的潜在药物也表现出良好的应用前景。促分裂原活化的蛋白激酶通路及磷脂酰肌醇-3-激酶/蛋白激酶B通路作为导致黑色素瘤发生的重要途径,针对其中各靶点的抑制剂是目前研究的重点。同时,联合治疗改善了单一用药的高耐受性,增强了抗肿瘤活性,显示出明显优势,为临床治疗所用。In the past few years, a comprehensive and in-depth study of the oncogenes and signaling pathways involved in the pathogenesis and development of melanonla has been carried out,and the treatment options have also been significantly improved. At present, in addition to the targeted drugs already used in clinical treatment, some pending drugs for clinical research and potential drugs for basic research have also shown good application prospects. Mitogen-aetivated protein kinase pathway and phosphatidylinositol-3-kinase/protein kinase B pathway are important pathways leading to the development of melanoma, and inhibilors targeting each of lhese targets are the focus of current research. At the same time, combined lherapy has improved the tolerance of single drug, enhanced anti-tumor activity, showing obvious advantages in the clinical treatment.

关 键 词：黑色素瘤 靶向治疗 促分裂原活化的蛋白激酶通路 磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路 

分 类 号：R739.5[医药卫生—肿瘤]